121 related articles for article (PubMed ID: 35047122)
1. Efficacy of omarigliptin, once-weekly dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes.
Kawasaki E; Nakano Y; Fukuyama T; Uchida A; Sagara Y; Tamai H; Tojikubo M; Hiromatsu Y; Koga N
World J Diabetes; 2021 Dec; 12(12):2087-2095. PubMed ID: 35047122
[TBL] [Abstract][Full Text] [Related]
2. Dynamics of switching, adherence, and persistence of dipeptidyl peptidase-4 inhibitors use: A nationwide cohort study.
Ofori-Asenso R; Ilomaki J; Chin KL; Mazidi M; Zomer E; Bell JS; Magliano DJ; Liew D
Diabetes Res Clin Pract; 2019 Dec; 158():107909. PubMed ID: 31697992
[TBL] [Abstract][Full Text] [Related]
3. Treatment Burden on Once-Weekly Omarigliptin Versus Daily Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes: Randomized Controlled Trial (ONWARD-DPP4 Study).
Ishii H; Kamei N; Shimono D; Niiya T; Tosaki T; Kitazawa T; Suzuki D; Wakasa Y; Seino H; Oishi M; Ohashi H; Higami K; Akai H;
Diabetes Ther; 2023 Oct; 14(10):1639-1658. PubMed ID: 37468684
[TBL] [Abstract][Full Text] [Related]
4. A Randomized Controlled Trial of Vildagliptin Versus Alogliptin: Effective Switch From Sitagliptin in Patients With Type 2 Diabetes.
Shigematsu E; Yamakawa T; Oba MS; Suzuki J; Nagakura J; Kadonosono K; Terauchi Y
J Clin Med Res; 2017 Jul; 9(7):567-572. PubMed ID: 28611856
[TBL] [Abstract][Full Text] [Related]
5. Effects of omarigliptin on glucose variability and oxidative stress in type 2 diabetes patients: A prospective study.
Ohara M; Nagaike H; Fujikawa T; Kohata Y; Ogawa M; Omachi T; Sasajima R; Chiba H; Ara T; Sugawara A; Hiromura M; Terasaki M; Mori Y; Fukui T; Hirano T; Yokoyama H; Yamagishi SI
Diabetes Res Clin Pract; 2021 Sep; 179():108999. PubMed ID: 34390762
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Patient Satisfaction of the Weekly DPP-4 Inhibitors Trelagliptin and Omarigliptin in 80 Japanese Patients with Type 2 Diabetes.
Tosaki T; Kamiya H; Yamamoto Y; Himeno T; Kato Y; Kondo M; Yamada Y; Inagaki A; Tsubonaka K; Oshiro C; Katayama T; Hayasaki T; Nakaya Y; Fujiyoshi H; Nakamura J
Intern Med; 2017 Oct; 56(19):2563-2569. PubMed ID: 28883229
[TBL] [Abstract][Full Text] [Related]
7. Omarigliptin for the treatment of type 2 diabetes.
Tan X
Endocrine; 2016 Oct; 54(1):24-31. PubMed ID: 27372109
[TBL] [Abstract][Full Text] [Related]
8. Effects of the Once-Weekly DPP4 Inhibitor Omarigliptin on Glycemic Control in Patients with Type 2 Diabetes Mellitus on Maintenance Hemodialysis: A 24-Week Open-Label, Multicenter Randomized Controlled Study.
Yoshizawa Y; Hosojima M; Kabasawa H; Tanabe N; Ugamura D; Koda Y; Shimada H; Takasawa T; Ito T; Kitamura T; Kobayashi M; Suzuki Y; Narita I; Saito A
Diabetes Ther; 2021 Mar; 12(3):655-667. PubMed ID: 33474645
[TBL] [Abstract][Full Text] [Related]
9. A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control.
Gantz I; Okamoto T; Ito Y; Sato A; Okuyama K; O'Neill EA; Engel SS; Lai E;
Diabetes Ther; 2017 Aug; 8(4):793-810. PubMed ID: 28589493
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent.
Tang YZ; Wang G; Jiang ZH; Yan TT; Chen YJ; Yang M; Meng LL; Zhu YJ; Li CG; Li Z; Yu P; Ni CL
Diabetol Metab Syndr; 2015; 7():91. PubMed ID: 26500706
[TBL] [Abstract][Full Text] [Related]
11. Durability of Effectiveness Between Users of Once-Weekly Semaglutide and Dipeptidyl Peptidase 4 Inhibitors (DPP-4i) in US Adults with Type 2 Diabetes.
Tan X; Liang Y; Gamble C; King A
Diabetes Ther; 2024 Feb; 15(2):427-445. PubMed ID: 38060149
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus: A systemic review and meta-analysis.
Wang X; Li X; Qie S; Zheng Y; Liu Y; Liu G
Medicine (Baltimore); 2018 Aug; 97(34):e11946. PubMed ID: 30142816
[TBL] [Abstract][Full Text] [Related]
13. Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study.
Bae J; Lee MJ; Choe EY; Jung CH; Wang HJ; Kim MS; Kim YS; Park JY; Kang ES
Endocrinol Metab (Seoul); 2016 Mar; 31(1):161-7. PubMed ID: 26754588
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Patient Satisfaction of Dipeptidyl Peptidase-4 Inhibitor After Switching From Once-Daily DPP-4 Inhibitor to Once-Weekly Regimen.
Suzuki K; Hasegawa K; Watanabe M
J Clin Med Res; 2018 Aug; 10(8):641-647. PubMed ID: 29977422
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
Handelsman Y; Lauring B; Gantz I; Iredale C; O'Neill EA; Wei Z; Suryawanshi S; Kaufman KD; Engel SS; Lai E
Curr Med Res Opin; 2017 Oct; 33(10):1861-1868. PubMed ID: 28548024
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes.
Sheu WH; Gantz I; Chen M; Suryawanshi S; Mirza A; Goldstein BJ; Kaufman KD; Engel SS
Diabetes Care; 2015 Nov; 38(11):2106-14. PubMed ID: 26310692
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic-pharmacodynamic (dipeptidyl peptidase-4 inhibition) model to support dose rationale in diabetes patients, including those with renal impairment, for once-weekly administered omarigliptin.
Jain L; Chain ASY; Tatosian DA; Hing J; Passarell JA; Kauh EA; Lai E
Br J Clin Pharmacol; 2019 Dec; 85(12):2759-2771. PubMed ID: 31454094
[TBL] [Abstract][Full Text] [Related]
18. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.
Golightly LK; Drayna CC; McDermott MT
Clin Pharmacokinet; 2012 Aug; 51(8):501-14. PubMed ID: 22686547
[TBL] [Abstract][Full Text] [Related]
19. A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
Shankar RR; Inzucchi SE; Scarabello V; Gantz I; Kaufman KD; Lai E; Ceesay P; Suryawanshi S; Engel SS
Curr Med Res Opin; 2017 Oct; 33(10):1853-1860. PubMed ID: 28547998
[TBL] [Abstract][Full Text] [Related]
20. Vildagliptin vs liraglutide as a second-line therapy switched from sitagliptin-based regimens in patients with type 2 diabetes: A randomized, parallel-group study.
Takeshita Y; Takamura T; Kita Y; Otoda T; Kato K; Wakakuri H; Yamada M; Misu H; Matsushima Y; Kaneko S;
J Diabetes Investig; 2015 Mar; 6(2):192-200. PubMed ID: 25802727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
